RELATLIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 21:45:19 GMT 2025` Edited by `admin` on `Tue Apr 01 21:45:19 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG4
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	AF75XOF6W3
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

BMS-986016

Preferred Name

English

RELATLIMAB

Official Name

English

IMMUNOGLOBULIN G4, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3 PROTEIN) (HUMAN HEAVY CHAIN), DISULFIDE WITH HUMAN LIGHT CHAIN, DIMER

Systematic Name

English

BMS-986213 COMPONENT RELATLIMAB

Common Name

English

relatlimab [INN]

Common Name

English

Relatlimab [WHO-DD]

Common Name

English

RELATLIMAB [USAN]

Common Name

English

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE 3 PROTEIN (LAG-3, PROTEIN FDC, CD223 ANTIGEN))

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

641718

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

FDA ORPHAN DRUG

595017

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

NCI_THESAURUS

C134305

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

Code System Code Type Description

DRUG BANK

DB14851

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

NCI_THESAURUS

C111999

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

CAS

1673516-98-7

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

INN

10735

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

RXCUI

2596773

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

DAILYMED

AF75XOF6W3

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

WIKIPEDIA

Relatlimab

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

FDA UNII

AF75XOF6W3

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

SMS_ID

100000176271

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

CAS

1683572-29-3

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

ALTERNATIVE

USAN

CD-174

Created by admin on Tue Apr 01 21:45:19 GMT 2025 , Edited by admin on Tue Apr 01 21:45:19 GMT 2025

PRIMARY

From	To
1_22	1_95
1_147	1_203
1_261	1_321
1_367	1_425
2_22	2_95
2_147	2_203
2_261	2_321
2_367	2_425
1_134	3_214
1_226	2_226
1_229	2_229
2_134	4_214
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_297
N	2_297

Related Record Type Details


					AK0JDV1ZK5

LYMPHOCYTE ACTIVATION GENE 3 PROTEIN

TARGET -> INHIBITOR

Amount:

RELATLIMAB-RMBW

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					AF75XOF6W3

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER AVERAGE	PHYSICAL
Molecular Formula	CHEMICAL